Endurant II/IIs Stent Graft System
Medtronic Vascular · Decision date May 12, 2026
What did the FDA approve?
FDA records P100021/S132 as a supplement to PMA P100021, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated May 12, 2026.
FDA approval order statement
approval for updates to the labeling to reflect the 60-month data from the ANCHOR Registry Short Neck Cohort
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Cardiovascular
- Decision date
- May 12, 2026
- FDA change category
- Labeling Change - PAS
Regulatory record facts
- Identifier
- P100021/S132
- Regulatory pathway
- PMA supplement
- Applicant
- Medtronic Vascular
- Product code
- MIH
- Decision code
- APPR
- Decision date
- May 12, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT.
- Applicant
- Medtronic Vascular
- Product code
- MIH
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P100021/S129 · Related supplement
Endurant Stent Graft System, Endurant II Stent Graft System, Endurant IIs Stent Graft System
P100021/S131 · Related supplement
Endurant II/IIs Stent Graft System
P100021/S132 received
Application receipt date recorded by FDA.
P100021/S133 · Related supplement
Endurant Stent Graft System; Endurant II/IIs Stent Graft System; Endurant II AUI Stent Graft System
P100021/S134 · Related supplement
Endurant, Endurant II/lls Stent Graft System
P100021/S132 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P100021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA supplement | Sep 15, 2025 | FDA | |
Endurant II/IIs Stent Graft SystemP100021/S131 | Medtronic Vascular | PMA supplement | Oct 23, 2025 | FDA |
| Medtronic Vascular | PMA supplement | Jan 27, 2026 | FDA | |
Endurant, Endurant II/lls Stent Graft SystemP100021/S134 | Medtronic Vascular | PMA supplement | Feb 27, 2026 | FDA |
Explore the linked device profile
Other records with product code MIH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
RelayPro Thoracic Stent-Graft Delivery SystemP200045/S025 | Bolton Medical, Inc. | PMA supplement | Oct 28, 2026 | FDA |
| Cook, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Cook, Inc. | PMA supplement | Aug 4, 2026 | FDA | |
| Cook Medical Incorporated | PMA supplement | Aug 4, 2026 | FDA | |
| William Cook Europe Aps | PMA supplement | Aug 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic Vascular
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 3576 Unocal Pl., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P100021/S132
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




